United Therapeutics Corporation (NASDAQ: UTHR) is scheduled to reveal its financial results for the third quarter on Wednesday 30th October 2024. This disclosure will take place before market open, providing investors with significant information regarding the company's performance in the last three months period.
According to the forecasts of financial experts on Wall Street, the company is poised to announce an anticipated per share $6.41 profit for the quarter. Furthermore, the firm is expected to disclose a total revenue of $722.91 million for this specific period.
Financial experts on Wall Street have shared their predictions regarding the company's annual performance, estimating a total revenue of $2.83 billion. Additionally, they are expecting the company to report profit of $24.74 per share for the full year 2024.
In comparison to the same quarter of the prior year, the company's financial statement showcased a per share of income of $5.38. This was credited to the company's total revenue, which reached an impressive $609.4 million in that particular timeframe.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $5.85 | +11.6% | 714.90 M | +19.8% |
| Q1 2024 | $6.17 | +27.0% | 677.70 M | +33.7% |
| Q4 2023 | $4.36 | +63.3% | 614.70 M | +25.1% |
| Q3 2023 | $5.38 | +9.6% | 609.40 M | +18.1% |
| Q2 2023 | $5.24 | +117.4% | 596.50 M | +27.8% |
| *Growth on year-over-year basis | ||||
The business has scheduled a conference call on 30th October 2024 at 09:00 AM eastern time to discuss Q3 financial results.
United Therapeutics Corporation (UTHR) closed Monday's regular trading session at $349.71, marking a 0.30 percent gain. The stock fluctuated between $348.00 and $352.13 during the day, with a volume of 307.00 thousand shares.
